X

Drug Profile

Deslorelin - Takeda

Alternative Names: D-Trp-LHRH-PEA; LHRH agonist analogue; Somagard

Latest Information Update: 27 May 2021

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Salk Institute
Developer Shire; Takeda
Class Amino acids; Antineoplastics; Ethylamines; Hormones
Mechanism of Action Gonadotropin releasing hormone stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Precocious puberty
New Molecular Entity No

Highest Development Phases

Registered Precocious puberty
Discontinued Endometriosis; Polycystic ovary syndrome; Prostate cancer; Uterine leiomyoma

Most Recent Events

08 Jan 2019 Shire has been acquired and merged into Takeda
10 Mar 2003 A study has been added to the Endocrine disorders therapeutic trials section
15 Feb 2001 Discontinued-III for Prostate cancer in Europe (IV-injection)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com